Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bolin Pan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Medcomm|July 15, 2025
Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial StudyXu Chen, Ming Huang, Zehua Chen, et al.
Nature Communications|August 26, 2025
Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapyHengji Zhan, Hongjin Wang, Bolin Pan, et al.
The Clinical Respiratory Journal|August 8, 2024
A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk ModelJiaxin Li, Bolin Pan, Qiying Huang, et al.
Research (Washington, D.C.)|June 18, 2025
A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and Tumor Microenvironment Remodeling for Enhanced Bladder Cancer ImmunotherapyChengjunyu Zhang, Sen Liu, Jianhui Zhang, et al.
Nature Communications|March 31, 2026
Miniature and versatile genome regulation TnpB-ωRNA toolkits facilitate cancer immunotherapyJunlin Lu, Jiajian Lai, Liang Cheng, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 11, 2025
Engineering CRISPR System-Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer ImmunotherapyHongjin Wang, Hengji Zhan, Bolin Pan, et al.
Cell Reports. Medicine|April 2, 2026
Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinomaZehua Chen, Shengmeng Peng, Shi Fu, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Medcomm|July 15, 2025
Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial StudyXu Chen, Ming Huang, Zehua Chen, et al.
Nature Communications|August 26, 2025
Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapyHengji Zhan, Hongjin Wang, Bolin Pan, et al.
The Clinical Respiratory Journal|August 8, 2024
A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk ModelJiaxin Li, Bolin Pan, Qiying Huang, et al.
Research (Washington, D.C.)|June 18, 2025
A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and Tumor Microenvironment Remodeling for Enhanced Bladder Cancer ImmunotherapyChengjunyu Zhang, Sen Liu, Jianhui Zhang, et al.
Nature Communications|March 31, 2026
Miniature and versatile genome regulation TnpB-ωRNA toolkits facilitate cancer immunotherapyJunlin Lu, Jiajian Lai, Liang Cheng, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 11, 2025
Engineering CRISPR System-Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer ImmunotherapyHongjin Wang, Hengji Zhan, Bolin Pan, et al.
Cell Reports. Medicine|April 2, 2026
Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinomaZehua Chen, Shengmeng Peng, Shi Fu, et al.
Pageof 2